Key Stats
Founded: October 1, 1896
Headquarters: Basel, Switzerland
Founder: Fritz Hoffmann-La Roche
CEO: Thomas Schinecker (March 2023–present)
Chairman: Severin Schwan
Revenue: CHF 60.5 billion (~$68 billion, 2024)
Employees: ~103,000
Stock: SIX Swiss Exchange (RO, ROG); OTCQX (RHHBY)
Roche Holding AG, commonly known as Roche, is a Swiss multinational healthcare company and one of the world’s largest pharmaceutical and diagnostics corporations. Headquartered in Basel, Switzerland, Roche operates two divisions: Pharmaceuticals and Diagnostics. The company is the world’s leading provider of cancer treatments, with oncology accounting for approximately 34% of pharmaceutical revenues. In 2024, Roche reported group sales of CHF 60.5 billion (~$68 billion), making it one of the five largest pharmaceutical companies globally by revenue.
Fritz Hoffmann-La Roche founded the company on October 1, 1896, in Basel, at age 28. He pioneered the concept of industrial-scale pharmaceutical manufacturing with standardized packaging and quality control—ideas that were ahead of their time. The company early on made its name producing vitamin preparations, becoming the first to mass-produce synthetic vitamin C (1934) and later introducing the benzodiazepine class of tranquilizers (Valium, 1963). Roche acquired the polymerase chain reaction (PCR) patents in 1992, which transformed molecular diagnostics.
Two transformational acquisitions define modern Roche. In 2002, the company acquired a majority stake in Japan’s Chugai Pharmaceuticals, establishing a major presence in Asian biotech. In 2009, Roche completed its full acquisition of Genentech for $46.8 billion—one of the largest pharmaceutical deals in history—giving it full control of the pioneering South San Francisco biotechnology company that had developed blockbuster cancer drugs like Herceptin, Avastin, and Rituxan. Today, Genentech operates as a wholly owned but independent subsidiary. Descendants of the founding Hoffmann and Oeri families still control over 50% of Roche’s voting shares, providing unusual stability for a company of its size. The company has increased its dividend for 37 consecutive years.
Roche History
1896–1919
Founding & Early Years
Fritz Hoffmann-La Roche, a 28-year-old Basel native from a wealthy silk merchant family, founds F. Hoffmann-La Roche & Co. on October 1, 1896. Inspired by witnessing the 1892 cholera outbreak in Hamburg, Hoffmann is convinced that medicines should be industrially manufactured with standardized quality. Early successes include Thiocal (cough relief), Digalen (heart conditions), and Sirolin cough syrup (1898)—the company’s first bestseller, marketed for 60 years. By 1912, Roche operates in nine countries across three continents with 700+ employees. World War I devastates the company financially; Roche becomes a limited stock company in 1919 to survive. Fritz Hoffmann dies on April 18, 1920, succeeded by Emil C. Barell.
1920s–1950s
Vitamin Era
Under Emil Barell’s scientific leadership, Roche pioneers vitamin research. In 1934, Roche becomes the first company to mass-produce synthetic vitamin C under the brand name Redoxon—a landmark in industrial chemistry. U.S. headquarters establish in Nutley, New Jersey (1929). Alice Keller becomes Roche’s first female general manager (1925), eventually rising to senior executive. In 1956, researchers accidentally discover iproniazid, the first antidepressant, while synthesizing tuberculosis drugs. (Iproniazid was withdrawn in the early 1960s due to side effects.) The Vitamins and Fine Chemicals division grows to become a bulk supplier to feed, food, pharmaceutical, and cosmetics industries worldwide.
1957–1979
Benzodiazepine Era
In 1957, Roche introduces the benzodiazepine class of tranquilizers, with Librium (1960) and Valium (diazepam, 1963) becoming blockbuster drugs—at one point, Valium was the most prescribed drug in the world. Between 1968 and 1972, Roche expands research capacity: Roche Institute of Molecular Biology (Nutley, NJ, 1968), Basel Institute for Immunology (1969), and Nippon Research Centre (Japan, 1972). In 1976, an accident at a Roche subsidiary in Seveso, Italy, causes major dioxin contamination (the “Seveso disaster”), leading to stricter European chemical safety regulations. Roche partners with biotech startup Genentech in 1979 to develop interferon.
1982–1998
Diagnostics Expansion & Nobel Prizes
Roche acquires Biomedical Reference Laboratories (1982, $163.5 million), forming Roche Biomedical Laboratories—by the early 1990s, one of the largest U.S. clinical laboratory networks. Two researchers from the Basel Institute for Immunology win Nobel Prizes: Niels Kaj Jerne (1984, immunology) and Susumu Tonegawa (1987, antibody gene research). Roche purchases a 60% stake in Genentech (1990), gaining access to pioneering biotech capabilities. Roche acquires polymerase chain reaction (PCR) patents (1992) from Cetus Corporation, transforming molecular diagnostics. In 1994, Roche acquires Syntex ($5.3 billion). The 1995 FDA approval of saquinavir, Roche’s HIV protease inhibitor, helps launch the highly active antiretroviral therapy (HAART) era—within two years, U.S. AIDS deaths fall from 50,000 to 18,000 annually. Roche Biomedical Laboratories is sold to LabCorp (1995). Roche acquires Corange Ltd. (parent of Boehringer Mannheim) in 1998 for $11 billion, creating Roche Diagnostics.
1999–2008
Vitamins Exit & Oncology Focus
In 1999, Roche pleads guilty to global vitamin price-fixing conspiracy and pays $500 million in criminal fines to the U.S. The company divests its vitamins business (sold to DSM in 2003) to focus on pharmaceuticals and diagnostics. Fragrances and Flavors division (Givaudan) is spun off (2000). Roche acquires a majority stake in Japan’s Chugai Pharmaceuticals (2002), forming one of the world’s largest biotech enterprises. Tamiflu (oseltamivir), an antiviral for influenza licensed from Gilead (1996), becomes critical during H5N1 avian flu concerns (2005–2006). Roche acquires Ventana Medical Systems (2008, $3.4 billion), strengthening tissue diagnostics and companion diagnostics capabilities.
2009
Genentech Acquisition
After eight months of negotiations—beginning with a hostile $43.7 billion bid in July 2008—Roche completes the full acquisition of Genentech for $46.8 billion (March 2009), one of the largest pharmaceutical deals in history. Roche gains full control of blockbuster cancer drugs Herceptin, Avastin, and Rituxan, and Genentech’s South San Francisco R&D campus. The combined entity becomes the world’s largest biotechnology company. Genentech operates as a wholly owned but independent subsidiary, preserving its entrepreneurial culture. Roche’s U.S. headquarters relocate from Nutley, NJ, to Genentech’s South San Francisco campus.
2010–2019
Pipeline & Diagnostic Expansion
Roche continues targeted acquisitions: InterMune ($8.3 billion, 2014, pulmonary fibrosis), Foundation Medicine ($2.4 billion, 2018, genomic profiling), Spark Therapeutics ($4.3 billion, 2019, gene therapy). The Nutley/Clifton, NJ campus closes (2012–2013). Roche develops companion diagnostics pairing therapies with diagnostic tests—a personalized medicine strategy. New cancer drugs include Perjeta (2012), Kadcyla (2013), Tecentriq (2016), and Hemlibra (2017, hemophilia A, developed by Chugai). Severin Schwan serves as CEO from 2008 to February 2023.
2020–2025
COVID-19 & Leadership Transition
Roche Diagnostics plays a major role in COVID-19 testing, though subsequent pandemic-related revenue declines affect 2022–2023 results. In March 2023, Thomas Schinecker (formerly head of Roche Diagnostics) becomes CEO; Severin Schwan becomes Chairman. Biosimilar competition erodes legacy oncology blockbusters (Avastin, Herceptin, Rituxan). New growth drivers emerge: Vabysmo (eye diseases, $4 billion+ in 2024), Ocrevus (multiple sclerosis), Phesgo (breast cancer). Roche enters the obesity drug race with a $2.7 billion Carmot Therapeutics acquisition (2024). FY 2024 sees 7% sales growth to CHF 60.5 billion. Roche invests CHF 3+ billion in a new Basel R&D center (completed 2022–2023).
Founder
Fritz Hoffmann-La Roche (1868–1920)
Fritz Hoffmann was born on October 24, 1868, in Basel, Switzerland, the third child of Friedrich Hoffmann, a wealthy silk merchant, and Anna Elisabeth Merian. His family belonged to Basel’s social elite (“the Daig”), and his godparents included his uncle, the Mayor of Basel. After completing school in Basel, Hoffmann apprenticed at a bank in French-speaking Switzerland, then worked at a pharmaceutical company upon his return in 1889. Between 1891 and 1893, he gained experience in chemistry-related business in London and Hamburg.
The 1892 Hamburg cholera outbreak deeply affected Hoffmann, convincing him that medicines needed to be manufactured industrially with standardized quality and distributed internationally. In 1894, he opened a company with partner Max Carl Traub (Hoffmann, Traub and Company). When Traub departed in 1896, Hoffmann renamed the company F. Hoffmann-La Roche & Co. on October 1, 1896. The “La Roche” came from his wife Adèle La Roche (married May 2, 1895), following the Swiss custom of hyphenating married names.
Hoffmann was a visionary entrepreneur who recognized the importance of tying pharmaceutical manufacturing to academic research and emphasized standardized packaging and branding. The company’s early products included Thiocal, Digalen, and Sirolin cough syrup. By 1912, Roche operated in nine countries across three continents. World War I and the Russian Civil War devastated the company’s finances; Roche became a limited stock company in 1919 to survive. Fritz Hoffmann died on April 18, 1920, at age 51, leaving two sons (Emmanuel and Alfred) and a company that would become one of the world’s largest healthcare corporations. Descendants of the Hoffmann and Oeri families still control over 50% of Roche’s voting shares.
Major Acquisitions
Roche’s growth strategy has combined internal R&D with strategic acquisitions, particularly in biotechnology and diagnostics.
- 1990 – Genentech (60% stake, ~$2.1 billion)
- 1992 – PCR patents from Cetus Corporation
- 1994 – Syntex ($5.3 billion)
- 1998 – Corange Ltd./Boehringer Mannheim ($11 billion, created Roche Diagnostics)
- 2002 – Chugai Pharmaceuticals (majority stake, Japan)
- 2008 – Ventana Medical Systems ($3.4 billion, tissue diagnostics)
- 2009 – Genentech (remaining shares, $46.8 billion total)
- 2014 – InterMune ($8.3 billion, pulmonary fibrosis)
- 2018 – Foundation Medicine ($2.4 billion, genomic profiling)
- 2019 – Spark Therapeutics ($4.3 billion, gene therapy)
- 2024 – Carmot Therapeutics ($2.7 billion, obesity drugs)
Roche Revenue
Roche operates two divisions: Pharmaceuticals (~75% of revenue) and Diagnostics (~25%). Oncology drugs account for approximately 34% of pharmaceutical sales. The company faced revenue pressure in 2022–2023 from declining COVID-19 testing sales and biosimilar competition against legacy cancer drugs (Avastin, Herceptin, Rituxan), but returned to growth in 2024 driven by newer therapies like Vabysmo, Ocrevus, and Hemlibra.
Note: 2023 decline reflects COVID-19 testing revenue drop and biosimilar erosion. 2024 shows return to 7% growth driven by newer medicines.
Roche Competitors
Roche competes with global pharmaceutical giants, particularly in oncology, immunology, and diagnostics. Its unique combination of pharmaceuticals and in vitro diagnostics gives it a differentiated position in personalized medicine.
| Company | Headquarters | Focus Areas |
|---|---|---|
| Pfizer | New York, NY | Vaccines, oncology, rare disease, internal medicine |
| Johnson & Johnson | New Brunswick, NJ | Pharmaceuticals, medical devices, consumer health |
| Novartis | Basel, Switzerland | Oncology, cardiovascular, immunology, neuroscience |
| Merck & Co. | Rahway, NJ | Oncology (Keytruda), vaccines, infectious disease |
| AstraZeneca | Cambridge, UK | Oncology, respiratory, cardiovascular |
| Sanofi | Paris, France | Immunology, vaccines, rare disease, diabetes |
| AbbVie | North Chicago, IL | Immunology (Humira legacy), oncology, aesthetics |
| Bristol Myers Squibb | New York, NY | Oncology, cardiovascular, immunology |
| Eli Lilly | Indianapolis, IN | Diabetes, obesity (GLP-1), oncology, neuroscience |
| GSK | London, UK | Vaccines, respiratory, HIV, oncology |
FAQs
What is Roche famous for?
Roche is famous for several groundbreaking contributions to medicine. The company was the first to mass-produce synthetic vitamin C (1934, brand name Redoxon) and introduced the benzodiazepine class of tranquilizers, including Valium (1963), once the world’s most prescribed drug. Roche acquired the polymerase chain reaction (PCR) patents in 1992, enabling modern molecular diagnostics. Today, Roche is the world’s leading provider of cancer treatments and operates the largest in vitro diagnostics business globally. Through its subsidiary Genentech, Roche has pioneered major cancer drugs including Herceptin (breast cancer), Avastin (various cancers), and Rituxan (blood cancers).
Who owns Roche?
Roche has an unusual ownership structure for a company of its size. Descendants of founder Fritz Hoffmann-La Roche and his partner Max Oeri control over 50% of the company’s voting shares through a pool of family shareholders (~45%) and individual holdings (notably Maja Oeri, ~5%). This family control has provided long-term stability. The company is publicly traded on the SIX Swiss Exchange (RO, ROG) and over-the-counter in the U.S. (RHHBY). Swiss pharmaceutical company Novartis held approximately one-third of Roche shares until selling its stake in 2021.
What is the relationship between Roche and Genentech?
Genentech is a wholly owned subsidiary of Roche, but operates with significant independence. Roche first purchased a 60% stake in Genentech in 1990, recognizing the South San Francisco biotech pioneer’s potential. After years of partnership, Roche acquired the remaining shares in March 2009 for $46.8 billion—one of the largest pharmaceutical deals in history. The acquisition gave Roche full control of major cancer drugs like Herceptin, Avastin, and Rituxan. Genentech continues to operate from its South San Francisco campus and maintains its own research culture, while Roche’s U.S. headquarters relocated there from New Jersey.
What are Roche’s biggest drugs?
Roche’s leading pharmaceutical products in recent years include: Ocrevus (ocrelizumab, multiple sclerosis), Vabysmo (faricimab, eye diseases—over $4 billion in 2024 sales), Hemlibra (emicizumab, hemophilia A, developed by Chugai), Phesgo (pertuzumab/trastuzumab, breast cancer), and Tecentriq (atezolizumab, cancer immunotherapy). Legacy blockbusters Avastin (bevacizumab), Herceptin (trastuzumab), and MabThera/Rituxan (rituximab) face biosimilar competition but remain significant. The company is also developing obesity drugs following its 2024 acquisition of Carmot Therapeutics.
What is Roche Diagnostics?
Roche Diagnostics is Roche’s in vitro diagnostics division, accounting for approximately 25% of group revenue. It is the world’s largest diagnostics company, providing blood glucose meters for diabetes (Roche Diabetes Care), high-throughput analyzers for hospitals and labs (cobas systems), molecular diagnostic tests (including PCR-based COVID-19 tests), and tissue diagnostics through subsidiary Ventana (cancer pathology). The combination of diagnostics and pharmaceuticals enables Roche’s personalized medicine strategy, pairing companion diagnostics with targeted therapies—for example, HER2 testing with Herceptin for breast cancer.
